CEMEX SAB DE CV annual report, Q4 FY2020

CEMEX, S.A.B. de C.V. — FY2020 Form 20-F

Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone Q4 filing; the supplied filing does not provide a clear set of Q4-only financial results. Financial statements are prepared under IFRS as issued by the IASB. Amounts below are in U.S. dollars unless noted.

Business context and key financial metrics

CEMEX is a global producer and distributor of cement, ready-mix concrete, aggregates and related construction solutions. It reported operations across Mexico, the United States, EMEAA and South, Central America and the Caribbean (SCA&C).

MetricFY2020FY2019Change / context
Revenue$12.970bn$13.130bnDown 1%; currency movements affected reported results.
Gross profit / margin$4.179bn / 32.2%$4.305bn / 32.8%Profit and margin declined.
Operating earnings before other expenses, net$1.343bn$1.333bnUp 1%; margin approximately 10.3% versus 10.2%.
Operating EBITDA$2.460bn$2.378bnNon-IFRS measure; reported table values imply growth of about 3.4%.
Operating earnings (loss)($436m)$986mIncludes $1.779bn of other expenses, net.
Controlling-interest net income (loss)($1.467bn)$143mLoss reflects impairment and other charges.
Cash flow from operating activities$1.578bn$1.353bnAfter interest, perpetual-debenture coupons and income taxes; continuing operations contributed $1.563bn.
Capital expenditures$795m$1.033bnReduced from prior year; FY2021 estimate was $1.1bn, subject to change.
Cash and cash equivalents$950m$788mAt year-end.
Total debt plus other financial obligations$11.185bn$11.790bnExcludes $449m of perpetual debentures; 9% current and 91% non-current.

Year-end debt plus other financial obligations were 64% U.S.-dollar-denominated and 22% euro-denominated. The filing reports $1.058bn of maturities in 2021, $385m in 2022, $934m in 2023, $1.526bn in 2024 and $7.282bn after 2024. Current liabilities exceeded current assets by $1.117bn; management describes negative working capital as part of its operating strategy and says it expects operating cash flow and refinancing capacity to meet near-term obligations. The committed revolving facility had $1.121bn available at year-end.

Material changes versus the prior comparable period

  • Consolidated cement volumes rose 2% to 63.8 million tons; ready-mix concrete volumes fell 6% to 47.0 million cubic meters.
  • Revenue declined 1%, while operating earnings before other expenses, net increased 1%. Gross margin fell 0.6 percentage points.
  • Other expenses, net increased to $1.779bn from $347m, principally due to $1.020bn of U.S. goodwill impairment and $306m of impairment on idle fixed assets. CEMEX also recorded a $194m impairment of other intangible assets.
  • Operating cash flow after interest, coupons and taxes increased to $1.578bn. Debt plus other financial obligations declined $605m, according to the company.
  • Results varied substantially by market: U.S. revenue rose 6% in dollars and Mexico revenue declined 3%; Panama revenue fell 56%, while demand and operations in several European markets were adversely affected by pandemic restrictions.

Outlook, management commentary, risks and unusual items

Under “Operation Resilience,” management targets a consolidated Operating EBITDA margin of at least 20% and net leverage at or below 3.0x by December 2023, and seeks an investment-grade capital structure. The plan includes cost reductions, portfolio divestments and reinvestments, debt reduction, longer maturities, lower funding costs, digital initiatives and sustainability investment. CEMEX reported $280m of cost-saving initiatives in 2020 and approximately $0.7bn of asset sales announced or completed. These are targets and management expectations, not guarantees.

The pandemic caused temporary restrictions, lower demand and interruptions in some markets. Management identified continuing uncertainty around new variants, vaccination, government measures, recovery and stimulus. Other principal risks include construction-market cyclicality, foreign-exchange exposure, energy and fuel costs, environmental and climate regulation, refinancing and covenant compliance, and ongoing litigation and investigations.

Subsequent financing disclosed in the report included the January 2021 issuance of $1.75bn of 3.875% senior secured notes due 2031, followed by redemptions of the 2026 notes and the remaining 2025 notes in February and April 2021. These transactions are not reflected in the 2020 year-end debt figures. Other matters to monitor include the delayed Maceo plant commissioning in Colombia, which remained dependent principally on access-road construction; tax proceedings in Spain and Colombia; and U.S. and other antitrust and corruption investigations. Management states that the SEC and DOJ investigations’ outcomes and potential sanctions could not be assessed.

The auditors issued unqualified opinions on the IFRS financial statements and internal control over financial reporting. KPMG identified goodwill impairment testing and certain tax and legal proceedings as critical audit matters. The filing reports no material off-balance-sheet arrangements.

Important facts for investors to verify

  • Reconcile the reported Operating EBITDA values ($2.460bn versus $2.378bn) with management’s statement that the increase was 0.3%; the filing text does not provide a clear reconciliation of that growth-rate discrepancy.
  • Review the $1.520bn impairment charge, particularly the U.S. goodwill valuation assumptions, sensitivity analyses and potential for further impairment.
  • Confirm current debt, liquidity, covenant headroom and the effect of the post-year-end notes issuance and redemptions; reported debt metrics exclude perpetual debentures and use definitions that may differ from facility-agreement calculations.
  • Assess whether the 2023 margin and leverage targets remain achievable given market conditions, planned divestments, capital spending and refinancing requirements.
  • Track the Maceo project’s access-road and operating status, and developments in material tax cases and regulatory investigations.